Novo Nordisk A/S (NVO)
GPW
175.12
+3.46 (+2.02%)
Closed
Aug 25, 2026
Day's Range
173.64175.12
52 wk Range
129.26231.00
Financial Statements - NVO - Novo Nordisk A/S
Revenue
309.06B▲ 88.2%
Net Income
102.43B▲ 79.4%Net Margin 33.1%
EBITDA
150.65B▲ 92.5%
Free Cash Flow
28.98B▼ 26.4%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Sales | 309.06B | 164.20B |
| Cost of Goods | 58.78B | 25.17B |
| Gross Profit | 250.27B | 139.03B |
 Operating Expense | - | - |
| Operating Income | 127.65B | 72.56B |
| Non-Operating Interest | - | - |
| Other Income Expense | 6.06B | -597.68M |
| Pre Tax Income | 130.54B | 71.92B |
| Income Tax | 28.10B | 14.81B |
| Net Income | 102.43B | 57.10B |
| EPS Basic | 23.06 | 22.67 |
| EPS Diluted | 23.03 | 22.63 |
| Basic Shares Outstanding | 4.44B | 2.51B |
| Diluted Shares Outstanding | 4.44B | 2.51B |
| Ebit | 134.74B | 72.84B |
| Ebitda | 150.65B | 78.26B |
| Net Income Continuous Operations | 102.43B | 57.10B |
| Minority Interests | - | - |
| Preferred Stock Dividends | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
